Comments
Aurobindo Pharma will seek approval from its shareholders for an enabling resolution to raise up to $600 million (about ₹3,980 crore). In January, its shareholders had approved a $350-million QIP issue but the company did not raise the funds due to volatile market.
The resolution had a validity period of one year. Hence, the board is again seeking shareholders’ nod for the revised amount, proposed to be raised either through FCCBs, ADRs, GDRs, QIP or QFIs.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.